By the help of our extensive experience in antibody discovery and development, Creative Biolabs is dedicated to providing a variety of Next-IO™ programs to our partners regarding novel therapeutic antibody developments. This program aims to develop the therapeutic mAb against KIR2DL1-3, one checkpoint expressed on NK cells to enhance the NK cell cytotoxicity.
Working as the first line of defense against transformed tumor cells and other infections, NK (natural killer) cell is the key component in the immune system. There are a variety of activating and inhibitory receptors expressed on NK cells contributes to protein expression and immune responses. For patients with cancers, restoring NK cell cytotoxicity is an important milestone. Killer cell immunoglobulin-like receptor (KIR)2DL1, 2, 3, a type of NK cell, is an inhibitory receptor that could bind to MHC class I molecules. This interaction can induce the suppressive signals to further inhibit NK cell immune responses. The inhibition is mediated by the immunoreceptor tyrosine-based inhibition motif (ITIM) in the cytoplasmic region (see Fig.1).
Fig.1 Inhibition and activation of NK cells mediated by KIR2DL and KIR2DS.1
Activation and inhibition signals are key features to determine when accessing the activity of NK cells. In patients with cancers, either inhibitory receptors on NK cells or the inhibitory ligands expressed on tumor cells get upregulated. The interactions between inhibitory receptors and ligands initiate inhibitory signals transduction to prevent NK cells activation. From this, we believe blocking the inhibitory receptors via anti-KIR2DL1-3 mAbs can restore the NK cell anti-tumor activity (see Fig.2). Our anti-KIR2DL1, 2, 3 antibody program aims to develop therapeutic mAb against KIR2DL1-3. We are dedicated to pushing this program forward to the pre-IND as soon as possible. Other than monoclonal antibody, we also open to co-develop combination strategies, and other antibody modalities, such as a bispecific antibody, etc.
From the data, we learn that the KIR acts as a potential therapeutic target for cancer immunotherapy. For any additional assistance, please feel free to reach out to our scientists.
We have extensive experience in performing comprehensive program developments and effective problem-solving. For our Next-IO™ programs, we are committed to promoting the program to the pre-IND stage within about 1.5 years. The accurate timeline will be determined on a case-by-case basis. Here is a draft timeline for your glance.
Fig.2 The timeline of Next-IOᵀᴹ programs.
Creative Biolabs is seeking potential partners to develop the novel therapeutic mAbs against KIR2DL1-3 together. With the help of our senior scientists and extensive experience, we are committed to pushing the program forward. “Benefits sharing and risks sharing” are the promises always in our minds. If you are interested in our Next-IO™ programs, please feel free to contact us for further communication.
For Research Use Only | Not For Clinical Use
Download our brochure